Our current clinical research is focused on metabolic bone disorders including fibrodysplasia ossificans progressiva (FOP). Our observational studies include patient registries and sample biobanking for rare bone diseases. In addition, our team is involved in multiple Phase 2 and Phase 3 interventional studies for metabolic bone diseases.
The Metabolic Bone Clinic
The UCSF Metabolic Bone Clinic in the Division of Endocrinology and Metabolism focuses in rare, genetic, or unusually complicated bone diseases. Our experts include Drs. Edward Hsiao, Dolores Shoback, and Steven Harris. We also work closely with other divisions at UCSF, including Medical Genetics, Orthopedics, Nephrology, and Medical Genetics.
For more information, and instructions for referrals to the clinic, please visit the UCSF Division of Endocrinology website: UCSF Metabolic Bone Clinic
Active Clinical Trials
For updated information about our ongoing clinical trials, please see the following links at clinicaltrials.gov:
- An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)
- Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral IPN60130 for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).
- A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥ 14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parental Studies.
- An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.